Studies
List of Studies being conducted at CARE
Acclaim
Enrolling, Lipoprotein (a)
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a…
Tandem
Enrolling, Cholesterol
The study is a placebo-controlled, double-blind, randomized, phase 3 study in participants with heterozygous familial hypercholesterolemia…
Tharros
Enrolling, COPD
THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a…
V-Prevent
Enrolling, Cholesterol
The purpose of this study is to evaluate inclisiran sodium 300 mg s.c. (equivalent to 284 mg inclisiran) compared to placebo on reducing the…
Synchronize
Enrolling
The purpose of this study is to find out whether people with overweight or obesity who take a medicine called survodutide (BI 456906) are…
Hermes
Enrolling, Heart Failure
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will…
Kallyope
In Follow Up, Weight Loss
The main purpose of this study is to assess the change in baseline in body weight after 13 weeks of treatment with K-757 alone and in…
Merck Cholesterol
Enrolling, Cholesterol
The goal of this study is to evaluate the efficacy, safety, and tolerability of MK-0616 in adult participants with hypercholesterolemia. The…
Power HF
Enrolling, Heart Failure
The purpose of this study is to evaluate the efficacy of the medication JTT-861 administered for 12 weeks in subjects with heart failure…
Librexia
Enrolling, Atrial Fibrillation
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and…
Achieve-4-GZGS
Enrolling, Diabetes
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type…
Oceanic (a)
Enrolling, Lipoprotein (a)
The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease…